ERBB2 and neoplasm: In agreement, increased Beclin1 activity (Becn1 knock-in mice expressing a mutated form of Beclin1 with decreased interaction to its inhibitor Bcl-2 or use of an autophagy-inducing peptide, Tat-Beclin1) prevented HER2-positive tumor xenograft progression [61].